3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
12
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Interventions
pembrolizumab
3
fludarabine
3
aldesleukin
3
Cyclophosphamide
3
cabozantinib
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
CTLA-4 Antigen
2
olaparib
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
darolutamide
1
Therapeutics
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Lutetium-177
1
Lutetium
1
Loperamide
1
Geriatric Assessment
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Fecal Microbiota Transplantation
1
Exercise
1
Continuous Positive Airway Pressure
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
olaparib
×
90 days
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled